Protein Contour Company Ltd.

Established in: 1991

The company employs highly skilled researchers and technicians, most with scientific degrees in chemistry, biology or medicine. The company's partner in a number of projects is FGUP State Research Institute of High-Purity Biopharmaceuticals Federal Unitary Enterprise of the Federal Medical and Biological Agency.

Since its foundation, the company has developed a wide range of technological solutions, which have greatly contributed to the establishment and evolution of clinical immunology in this country.

The company's major achievement is the process for the manufacture of recombinant human erythropoietin (INN: epoetin alpha). Protein Contour owns three patents for epoetin-alpha manufacturing process.

The company was the first in Russia to develop the active substance whose quality and manufacturing cost are competitive with Western substitutes.

In terms of its composition, biological and immunological properties, epoetin alpha is identical to human erythropoietin. Administration of epoetin alpha increases the levels of haemoglobin and haematocrit and improves the blood supply to tissues and heart performance. The application of epoetin alpha has the best effect on anaemias caused by chronic kidney disease, cancer, transplantation, AIDS, hepatitis C, rheumatoid arthritis, chronic and aging-associated diseases.

The high quality of recombinant human erythropoietin and the low cost of its manufacturing process have made it possible for products made on its basis to claim a major share of the Russian epoetin market in terms of hospital procurement.

The company has a number of high-tech solutions on the drawing board for the manufacture of recombinant substitutes.

протек-свм спарго транссервис протек ригла сотекс протеин протек фонд